Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report

Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report

Crizotinib, the first clinically available inhibitor of anaplastic lymphoma kinase (ALK) gene rearrangement, is generally well tolerated. In contrast, neutropenia induced by crizotinib is a commonly reported grade 3 or 4 adverse event. In such cases, interruption and dose reduction of crizotinib mig...

Full description

Bibliographic Details
Main Authors: Jun Osugi, Yuki Owada, Takumi Yamaura, Satoshi Muto, Naoyuki Okabe, Yuki Matsumura, Mitsunori Higuchi, Hiroyuki Suzuki, Mitsukazu Gotoh
Format: Article
Language:English
Published: Karger Publishers 2016-01-01
Series:Case Reports in Oncology
Subjects:
Non-small cell lung cancer
Alectinib
Neutropenia
Crizotinib
Anaplastic lymphoma kinase gene rearrangement
Online Access:http://www.karger.com/Article/FullText/443662

Internet

http://www.karger.com/Article/FullText/443662

Similar Items